Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,262 across all filing types
Latest filing 2024-08-27 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
半年报监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolution passed at the second meeting of the fifth Supervisory Board of the company. It includes details about the meeting date, participants, and the approval of the company's 2024 semi-annual report and related financial matters. The document does not contain the actual semi-annual report or detailed financial statements but rather certifies the approval and legality of the report prepared by the board. The length is short (929 characters), and it serves as an official announcement of the meeting's resolutions rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a formal disclosure of supervisory board decisions and approvals, not the interim report itself.
2024-08-27 Chinese
半年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 95% confidence The document is a summary table detailing non-operating fund occupation and other related party fund transactions for the half-year period of 2024. It includes financial figures such as balances, interest, and repayments related to affiliated parties and subsidiaries. The document is relatively short (1499 characters) and appears to be a financial disclosure related to related-party transactions for a half-year period. It is not a full interim or quarterly report since it lacks comprehensive financial statements or substantive financial analysis. It is also not an announcement of a report publication but a specific financial summary table approved by the board. Such disclosures typically fall under Regulatory Filings (RNS) as they are compliance-related financial disclosures that do not constitute a full financial report or earnings release.
2024-08-27 Chinese
半年报董事会决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the company's fifth board of directors' second meeting, held on August 27, 2024. It includes details about the approval of the company's 2024 semi-annual report and related financial disclosures, but does not contain the actual financial statements or detailed report content itself. The document serves as a notice of the board meeting decisions and references where the full semi-annual report and related documents are disclosed. Given the short length (1126 characters) and the nature of the content as a meeting resolution announcement rather than the report itself, this fits the category of a Regulatory Filing (RNS) rather than an Interim/Quarterly Report (IR) or Annual Report (10-K).
2024-08-27 Chinese
2024年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2024 年半年度财务报告" which translates to "2024 Semi-Annual Financial Report". It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and changes in equity for the half-year period ending June 30, 2024. The document length is substantial (15,000 characters) and includes actual financial data and analysis for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). There is no indication that this is merely an announcement or a certification, and the content is comprehensive financial reporting for a half-year period. H1 2024
2024-08-27 Chinese
2024年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "2024 年半年度报告摘要" which translates to "2024 Semi-Annual Report Summary." It contains detailed financial data for the half-year period, including revenue, net profit, earnings per share, and asset information. It also discusses business operations, strategic initiatives, and management commentary on performance and outlook. The length of the document (7176 characters) and the presence of substantive financial data and analysis confirm it is a financial report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-27 Chinese
关于复方聚乙二醇（3350）电解质口服溶液获得上市许可受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding the acceptance of a drug registration application by the National Medical Products Administration (国家药品监督管理局). It details the drug name, application number, applicant, and intended use, and includes a risk warning about the approval process. The document is short (849 characters) and serves as an official notice of a regulatory event rather than a financial report or detailed filing. It does not contain financial data, management discussion, or audit information. It is not a report but an announcement of a regulatory milestone related to product approval. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-08-22 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.